Bristol Myers Squibb, Cellares Ink $380M Deal to Manufacture CAR T-Cell Therapies

Posted on April 23, 2024 by admin

Per the agreement, Cellares will integrate and automate some of Bristol Myers Squibb’s CAR T-cell therapies into its Cell Shuttle program.